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Canine Total Orthotopic Small Bowel Transplantation Under FK 506 
F. Yoshimi, K. Nakamura, Y. Zhu, M. Suzuki, Y. Funakoshi, G. Carrieri, Y. Wu, H. Furukawa, 
A.J. Demetris, S. Todo, and T.E. Starzl 
EXPERIMENTS of small bowel or multivisceral trans-plantation in rodents have established the potency of 
FK 506 in preventing intestinal rejection. l -4 We present 
here observations with the more difficult model of canine 
small bowel transplantation. 
MATERIALS AND METHODS 
Adult mongrel dogs of both sexes. weighing 12.5 to 29.0 kg. were 
used. Under anesthesia with isoflurane. the entire small bowel 
except the duodenum and 5 cm of the terminal ileum was isolated 
with its vascular pedicle. and excised. The graft was perfused on 
the back table with cold lactated Ringer's solution containing 2500 
u/L of heparin. The transplantation technique was essentially the 
same as that originally described by Lellihei et al.s in which the 
grafts were exchanged between the donor and the recipient. The 
superior mesenteric artery and the superior mesenteric vein were 
anastomosed end-ta-end. A 100cm segment of graft-distal ileum 
was exteriorized. as a Thiry-Vella loop. for visual monitoring and 
postoperative mucosal biopsies. 
The animals were divided into nine groups. according to treat-
ment (Table I). Thirty-four (33%) of the original 103 animals who 
died within 5 days from various technical causes were excluded 
from the final analysis. Except for the intramuscular OM) group 
(B). treatment was continued daily until animals died or were 
killed with an anesthesia il\iection when they became lethargic or 
lost more than 40% of their preoperative body weight. Control 
animals with autotransplantation were killed I year postopera-
tively. 
Posttransplant observations were of the clinical course. stools. 
and appearance of the isolated segment stoma. Measurements 
were of body weight. electrolytes. and blood chemistries. FK 506 
plasma levels were monitored by a standardized method of 
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Table 1. Experimental Groups 
FK506 
Group n (mgIkg per day) 
A-1 8 0.00 
A-2 5 0.20 
A-3 6 0.00 
A-4 7 0.05 
A-5 6 0.075 
A-6 11 0.10 
A-7 8 0.20 
B 7 1.00 
C 11 1.50 
Graft 
Auto 
Auto 
Allo 
Aile 
Aile 
Aile 
Allo 
Allo 
Aile 
'Intramuscular FK 506 (1 mglkg per day) was given on postoperative days 3.4. 
and 5. . , . 
. t: .... 
enzyme immunoassay.6 Maltose absorption test (0.5 mglkg) was 
performed periodically using the modified method of Billiar et al. 7 
Tissues obtained from stomal biopsies or at postmortem exam-
inations were fixed with 10% buffered formalin and stained with 
hematoxylin-eosin. Histological features of acute rejection were 
similar to those reported in treated4 or untreated.H rats and 
included hemorrhagic mucosal necrosis. lymphocytic infiltration 
of the lamina propria. epithelial damage. and lacteal dilatation. 1M 
and perineural mononuclear cell infiltrate. obliterative arteritis. 
and thickening of the muscular layer with accompanying mucosal 
alterations including villous atrophy were features of chronic 
rejection. 
RESULTS 
Autotransplantation 
Untreated dogs with autografts (A-1) lived indefinitely. 
Mean survival after autotransplantation was reduced to 31 
days when 12 mg/kg IV FK 506 was given (Fig 1). The 
usual cause of death was lethal emaciation. 
Allotransplantation 
In contrast. untreated recipients of allografts (A-3) died of 
rejection within 10 days (mean 7.8). Mean survival of 57.5 
days was obtained in dogs treated with 0.1 mg/kg per day 
IV FK 506 (A-6) or with 0.075 mg/kg per day (A-5) (Fig 1). 
When the IV dose was increased to 0.2 mg/kg per day 
(A-7), mean survival was reduced to 23.3 days. 
Mean survival of the animals treated with 1 mg/kg 1M 
FK 506 on postoperative days 3, 4, and 5 only (group B) 
was 17.7 days (Fig 1). Survival using daily oral treatment 
with 1.5 mg/kg (group C) was 22.8 days. 
In untreated recipients, or those with the lowest dose of 
FK 506. the cause of death was always acute rejection with 
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SMALL BOWEL TRANSPLANT IN DOGS 
Graft FK 
o 
Mean Survival Days· 
20 40 60 80 100 120 365 
Auto 
~~~~~~~~~~~-L-~~~~ o 
0.2 
Allo 0 
0.05 
0.075 
0.1 
0.2 
*_±s.d. 
Fig 1. Mean survival days of the animals treated with IV FK 506. 
FK 506 (mg/kg per day) was given daily until animals died or were 
sacrificed. Autotransplant control animals (no FK 506) were sac-
rificed at 1 year. 
hemorrhagic necrosis of the mucosa. At the IV dose of 0.1 
mg/kg per day, half of the animals died. either of acute 
rejection or a combination of acute or chronic rejection. In 
animals dying after I month, many of the grafts had 
hypertrophic thickening of the muscular layer and neu-
ronal hypertrophy. These findings were not present in any 
of the intestinal autografts which, in untreated animals. 
were sampled at a much later time. 
At the highest IV FK 506 dose. one-fourth of the dogs 
died of rejection, and the remaining animals died of lethal 
emaciation. Clinical or histological graft-versus-host dis-
ease (GVHD) was not seen in any of these animals. 
Absorption 
Preoperatively, and I week after transplantation (Fig 2), 
elevations of blood glucose after oral maltose administra-
tion were not different in the autograft group (A-I) com-
pared to the allograft groups with CA-6) or without FK 506 
treatment (A-3). Later postoperative studies were not 
systematically obtained. 
Plasma Levels of FK 506 
Five days after transplantation. plasma concentrations 
varied according to the route of administration. In the IV 
treatment groups, plasma FK 506 levels were between 0.15 
and 0.24 nglmL at doses from 0.05 to Q.l mglkg per day. 
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Fig 2. Maltose absorption test before intestinal transplantation 
(PRE) and 1 week postoperatively in animals receiving autografts 
without treatment. or allografts with or without 0.1 mglkg per day IV 
FK 506. Net increases of mean blood glucose levels (mg/dL) after 
0.5 mg/kg of maltose administration are shown. 
The highest FK 506 dose of 0.2 mglkg per day gave 1.56 
nglmL as a mean trough level at 5 days. Mean FK 506 
plasma levels were 1.0 nglmL and 1.04 nglmL in the 1M 
group (group B) and in the oral group (group C), respec-
tively. 
DISCUSSION 
Early research on small bowel transplantation in isolation5 
or as part of multivisceral grafts9 was with the nonimmu-
nosuppressed dog. Many subsequent studies have been 
performed in dogs to evaluate the immunosuppressive 
agents in bowel transplantation. 10-12 histopathologic 
changes,l3·14 and the absorptive function of allografts. IS 
The present study is the first in dogs to assess the efficacy 
of FK 506 for small bowel transplantation. The results 
were comparable to those previously reported with Cy A. 12 
FK 506 significantly prolonged animal survival. especially 
at IV doses of 0.075 and 0.1 mglkg per day. The maximum 
survival was 258 days with the latter dose. Higher doses 
caused lethal emaciation similar to that reported in dogs in 
canine renal and hepatic transplantation experiments. 16-18 
Although we have concluded that the dog is a difficult if 
not inappropriate species for most transplant studies with 
FK 506, the wealth of information in past canine experi-
ments with the bowel as well as other transplanted organs 
prompted this study. The high mortality, as in our earlier 
studies of kidney l6.17 and liver transplantation. 18 was 
partly ascribable to drug toxicity, which precluded doses 
high enough to consistently prevent rejection. Rejection 
appeared more difficult to control than with the canine 
kidney or liver with which long survival could be achieved 
with a short course of therapy. 16 The intestinal recipients 
of the present study had little benefit from a 3-day 1M 
